The study, conducted at the Breast Centre of the Fourth Hospital of Hebei Medical University, meticulously examined peripheral blood samples from 107 breast cancer patients alongside 33 healthy control subjects. By employing sophisticated flow cytometry techniques, the research team quantitatively analyzed the presence and levels of immunosuppressive cellular populations, particularly focusing on the heterogeneity of MDSCs, including polymorphonuclear (PMN-MDSCs) and monocytic (M-MDSCs) subsets, alongside Tregs. These immune cells are notorious for their role in tumor-induced immunosuppression, facilitating cancer progression by subverting the host’s antitumor immune response.

One of the pivotal revelations from this investigation is the marked elevation of MDSCs and Tregs in breast cancer patients relative to healthy individuals. The statistical significance of this increase (p < 0.05) underscores the systemic immunological alterations elicited by malignant processes. Notably, the expansion of these cells is not merely a peripheral phenomenon but intricately linked to the aggressiveness and spread of breast cancer, as evidenced by the robust positive correlation with lymph node metastasis (p < 0.001 for MDSCs, PMN-MDSCs, and Tregs).

Lymph node involvement remains a cardinal prognostic factor in breast cancer, frequently dictating therapeutic strategies and survival outcomes. Conventional methods of detecting metastatic spread involve invasive biopsies or imaging modalities with varying sensitivities. Thus, the identification of reliable blood-based biomarkers that accurately reflect metastatic risk presents an attractive, less invasive clinical tool. The current study’s findings suggest that assessing the combined levels of MDSCs and Tregs in peripheral blood can significantly enhance the predictive accuracy for lymph node metastasis, surpassing the diagnostic value of individual markers.

Receiver operating characteristic (ROC) curve analyses further corroborated these insights. Among the evaluated cell populations, Tregs demonstrated the highest individual area under the curve (AUC = 0.766), affirming their critical role in mediating tumor immune evasion and supporting metastatic dissemination. Importantly, the amalgamation of MDSCs and Treg assessments yielded a combined AUC exceeding that of any single parameter, emphasizing the synergistic potential of these biomarkers when evaluated concomitantly.

Diverging into the biology of these immune suppressive cells, MDSCs represent a heterogeneous group of immature myeloid cells that accumulate in cancer and other pathological conditions, exerting potent immunosuppressive functions primarily through the inhibition of T cell activation and proliferation. Their two principal subsets, PMN-MDSCs and M-MDSCs, differ in morphology, surface markers, and mechanisms of suppression. This study elucidates that both subsets are elevated in breast cancer and significantly associated with metastatic burden, although M-MDSCs portrayed a somewhat weaker yet still relevant association (p = 0.045).

Tregs, characterized by the expression of transcription factor FOXP3, are pivotal regulators of immune homeostasis but often co-opted by tumors to foster a microenvironment conducive to immune tolerance. By curtailing effector T cell responses and secreting immunosuppressive cytokines, Tregs can effectively shield cancer cells from immune surveillance. The current research concretely links heightened peripheral Treg levels with increased lymphatic spread, reinforcing their dual-edged role within the cancer-immune interplay.

Beyond its clinical implications, this study provides mechanistic insights into how the systemic immune milieu shapes tumor evolution and metastasis. The simultaneous elevation of MDSCs and Tregs illustrates a coordinated immunosuppressive network that not only promotes primary tumor development but facilitates dissemination via lymphatics. This paradigm underscores the significance of targeting multiple immune subsets to disrupt metastatic progression effectively.

Furthermore, the ease of measuring these cellular populations through flow cytometry in peripheral blood samples suggests considerable practicality for clinical deployment. Routine monitoring of MDSC and Treg levels could potentially guide risk stratification, inform surgical planning, and tailor adjuvant therapies, ultimately contributing to personalized breast cancer management.

The study also raises intriguing questions for future research, such as the potential for therapies that selectively modulate MDSCs and Tregs to restrain lymph node metastasis. Immunotherapeutic strategies, including checkpoint inhibitors and cell-depleting agents, might be optimized by incorporating biomarker-driven patient selection based on these immune profiles.

From a translational standpoint, the findings emphasize a shift towards integrating immunological biomarkers into conventional oncological workflows. Such integration could expedite early detection of metastatic risk and improve prognostication with minimal patient discomfort compared to existing invasive diagnostics.

Importantly, this research aligns with the broader scientific push to elucidate the tumor microenvironment’s systemic ramifications, recognizing cancer as not merely a localized entity but one profoundly influenced by host immunity. It reaffirms the concept that peripheral immune alterations mirror and potentially dictate tumor behavior.

The robustness of the data, underpinned by a well-characterized patient cohort and rigorous analytical methods, strengthens confidence in these conclusions. However, the authors acknowledge the necessity for larger, multi-center studies to validate these findings across diverse populations and breast cancer subtypes.

In summary, the combined elevation of MDSCs and Tregs emerges as a powerful biomarker axis predicting lymph node metastasis in breast cancer. This discovery portends a new era of immunological diagnostics that harness systemic immune shifts to anticipate metastatic progression, ultimately guiding therapeutic interventions more accurately and improving patient prognoses.

With breast cancer remaining a leading cause of cancer-related morbidity and mortality worldwide, innovations such as this illuminate pathways to earlier intervention and better tailored treatment algorithms. As research continues to unravel the intricacies of tumor-immune dynamics, integrating immune profiling into routine care promises profound impacts on breast cancer management and beyond.

Subject of Research: Investigation of the clinical significance of myeloid-derived suppressor cells (MDSCs), including polymorphonuclear (PMN-MDSCs) and monocytic (M-MDSCs) subsets, and regulatory T cells (Tregs) in peripheral blood of breast cancer patients for predicting lymph node metastasis.

Article Title: Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer.

Article References:
Zhang, H., Yin, X., Wang, S. et al. Combined elevation of myeloid-derived suppressor cells and Tregs predicts lymph node metastasis in breast cancer. BMC Cancer 25, 1806 (2025). https://doi.org/10.1186/s12885-025-15277-4

Image Credits: Scienmag.com

DOI: 10.1186/s12885-025-15277-4 (Published 24 November 2025)

Hormone receptor-positive breast cancers have long been recognized for their comparatively favorable prognoses, largely due to responsiveness to endocrine therapies targeting estrogen and progesterone receptors. Yet, it has become increasingly evident that loss of progesterone receptor expression among ER+ breast cancers signals a more aggressive disease course and resistance to conventional hormonal treatments. Despite this, the molecular mechanisms delineating ER+/PR+ from ER+/PR- cancers have remained elusive, impeding tailored therapeutic interventions.

To bridge this knowledge gap, the research team embarked on an integrative approach analyzing fresh tumor samples from carefully characterized patient cohorts. Five ER+/PR+ and five ER+/PR- tumor tissues underwent detailed proteomic profiling to catalog differentially expressed proteins. Complementing this, transcriptomic data encompassing 937 breast cancer cases from The Cancer Genome Atlas (TCGA) allowed for broad validation and correlation with clinical outcomes, including disease-specific and overall survival metrics.

Strikingly, survival analyses reaffirmed clinical suspicions: patients harboring ER+/PR- tumors exhibited significantly poorer 5-year disease-specific survival compared to their ER+/PR+ counterparts. This survival pattern was comparable to that observed in ER-/PR- patients, underscoring the aggressive nature linked to the absence of progesterone receptor expression despite maintained estrogen receptor positivity. Such findings heighten the urgency to decode the molecular drivers behind this disparity.

Proteomic assessment unveiled 186 proteins differentially expressed between the two subtypes, comprising 110 upregulated and 76 downregulated candidates in ER+/PR- tumors. Subsequent focal analyses employing Cox proportional hazards regression and Least Absolute Shrinkage and Selection Operator (LASSO) techniques distilled these findings to five key regulatory genes exhibiting significant prognostic value: HPN, FSCN1, FGD3, LRIG1, and TBC1D7.

Delving into these genes’ roles revealed a compelling paradigm—HPN, FSCN1, and FGD3 function as tumor suppressors, their diminished expression likely facilitating tumor progression and endocrine resistance in ER+/PR- cancers. Conversely, LRIG1 and TBC1D7 emerged as risk-associated genes, potentially driving oncogenic pathways and contributing to the poorer clinical outcomes observed. This gene signature offers an unprecedented molecular fingerprint for patient stratification and risk assessment.

By synthesizing these molecular signatures into a risk scoring model, the researchers demonstrated its predictive power in segregating patients into high- and low-risk groups with marked differences in survival probability. Such prognostic stratification is invaluable for guiding clinical decision-making, particularly in tailoring adjuvant treatments to individual tumor biology.

Beyond survival implications, functional enrichment analyses illuminated altered metabolic and signaling pathways underpinning ER+/PR- breast cancer biology. Key pathways such as galactose metabolism, glycolysis/gluconeogenesis, JAK-STAT signaling, and the pentose phosphate pathway were differentially engaged between risk groups. These metabolic shifts suggest potential vulnerabilities that could be exploited therapeutically to disrupt tumor growth and survival.

Immunologically, tumor microenvironment differences were notable, with high-risk groups showing altered infiltration patterns of immune effectors including CD8+ T cells and M1 macrophages. These immune landscape variations potentially influence tumor immune evasion, therapy response, and metastatic propensity. Understanding these nuances could inform the development of immunomodulatory strategies tailored for ER+/PR- breast cancer.

Crucially, drug sensitivity predictions derived from the OncoPredict algorithm indicated divergent therapeutic susceptibilities. Low-risk patients appeared more responsive to endocrine therapies, such as fulvestrant, reinforcing the continued utility of hormone blocking agents in this subgroup. Conversely, high-risk patients demonstrated enhanced sensitivity to chemotherapeutics like docetaxel, paclitaxel, and vinorelbine, advocating for chemotherapy consideration in these cases.

Supporting these in silico predictions, clinical data collected from 97 hormone receptor-positive breast cancer patients undergoing neoadjuvant chemotherapy exhibited higher rates of favorable pathological response (Miller-Payne scores of 4 and 5) in ER+/PR- patients compared to ER+/PR+ patients, consistent with the proposed chemoresponsiveness of the more aggressive subtype.

The study’s thorough validation using external Gene Expression Omnibus (GEO) datasets (GSE21653, GSE20685, and GSE42568) solidifies the robustness of their findings across diverse patient populations. Such rigorous cross-validation enhances confidence in the gene signature’s applicability in varied clinical contexts.

Collectively, this integrative proteomic-transcriptomic framework not only demarcates the molecular hallmarks distinguishing ER+/PR+ and ER+/PR- breast cancers but also lays a foundation for precision oncology. The identification of key genes and pathways offers actionable targets, while the risk scoring system empowers clinicians to customize therapy, balancing endocrine and chemotherapeutic modalities according to individual tumor biology.

As breast cancer management advances towards personalized medicine, insights from studies like this underscore the need to move beyond receptor status as a binary descriptor. Instead, a comprehensive molecular portrait encompassing gene expression, protein dynamics, metabolic pathways, and immune contexture is vital for optimizing outcomes.

Future research built on these findings may explore therapeutic interventions modulating the identified regulatory genes or their associated pathways. Additionally, immunotherapy combinations tailored to immune infiltration patterns observed could revolutionize treatment paradigms for ER+/PR- breast cancer patients.

Ultimately, unraveling the complexities of hormone receptor-positive breast cancer subtypes heralds a new era where molecularly informed strategies enhance survival, mitigate resistance, and improve quality of life. This study marks a significant stride in that direction, translating cutting-edge multi-omic science into clinically meaningful advances.

Subject of Research: Molecular mechanisms differentiating ER-positive/PR-positive and ER-positive/PR-negative breast cancer subtypes, focusing on integrated proteomic and transcriptomic analysis to inform prognosis and treatment strategies.

Article Title: Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer

Article References:
Lu, Z., Yang, J., Feng, Y. et al. Integrated proteomics and transcriptomics analysis reveals key regulatory genes between ER-positive/PR-positive and ER-positive/PR-negative breast cancer. BMC Cancer 25, 1048 (2025). https://doi.org/10.1186/s12885-025-14451-y

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14451-y